Den europeiske union - norsk - EMA (European Medicines Agency)

zoetis belgium sa - cefovecin (as sodium salt) - antibakterielle midler til systemisk bruk - dogs; cats - dogsfor behandling av hud og mykt vev infeksjoner, inkludert pyoderma, sår og abscesser forbundet med staphylococcus pseudintermedius, β-haemolytic streptokokker, escherichia coli og / eller pasteurella multocida. for behandling av urin-skrift infeksjoner assosiert med escherichia coli og / eller proteus spp. som adjuvant behandling til mekanisk eller kirurgisk periodontal terapi i behandlingen av alvorlige infeksjoner i gingiva og periodontal vev forbundet med porphyromonas spp. og prevotella spp. catsfor behandling av hud og mykt vev byller og sår forbundet med pasteurella multocida, usobacterium spp. , bacteroides spp. , prevotella oralis, β-hemolytiske streptokokker og / eller staphylococcus pseudintermedius. for behandling av urinveisinfeksjoner assosiert med escherichia coli.

Den europeiske union - norsk - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - guanfacin hydroklorid - attention deficit disorder med hyperaktivitet - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv må brukes som en del av en omfattende adhd behandling program, vanligvis inkludert psykologiske, pedagogiske og sosiale tiltak.

Norge - norsk - myHealthbox

bayer ag - fenheksamid 500 g/kg

Den europeiske union - norsk - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Den europeiske union - norsk - EMA (European Medicines Agency)

roche registration gmbh - metoksy polyetylen glykol-epoetin beta - anemia; kidney failure, chronic - antianemiske preparater - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5. treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.

Den europeiske union - norsk - EMA (European Medicines Agency)

pharmaand gmbh - peginterferon alfa-2a - hepatitis c, chronic; hepatitis b, chronic - immunostimulants, - chronic hepatitis b adult patients pegasys is indicated for the treatment of hepatitis b envelope antigen (hbeag)-positive or hbeag-negative chronic hepatitis b (chb) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (alt) and histologically verified liver inflammation and/or fibrosis (see sections 4. 4 og 5. paediatric patients 3 years of age and older pegasys is indicated for the treatment of hbeag-positive chb in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum alt levels. med hensyn til beslutningen om å innlede behandling i paediatric pasienter se kapittel 4. 2, 4. 4 og 5. chronic hepatitis c adult patients pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis c (chc) in patients with compensated liver disease (see sections 4. 2, 4. 4 og 5. for hepatitt c-virus (hcv) genotypen bestemt aktivitet, se kapittel 4. 2 og 5. paediatric patients 5 years of age and older pegasys in combination with ribavirin is indicated for the treatment of chc in treatment-naïve children and adolescents 5 years of age and older who are positive for serum hcv-rna. når du bestemmer deg for å starte behandling i barndommen, er det viktig å vurdere vekst hemming indusert ved kombinasjonsbehandling. den reversibilitet av vekst hemming er usikker. beslutningen om å behandle bør gjøres på en sak til sak-basis (se kapittel 4.

Den europeiske union - norsk - EMA (European Medicines Agency)

virbac s.a. - gentamicin sulfate, hydrocortisone aceponate, miconazole nitrate - otologicals, kortikosteroider og antiinfectives i kombinasjon - hunder - behandling av akutt otitis externa, og akutt forverring av residiverende otitis externa assosiert med bakterier utsatt for gentamicin og sopp er utsatt for miconazole, spesielt malassezia pachydermatis.

Norge - norsk - Statens legemiddelverk

dechra veterinary product a/s - mikonazolnitrat / klorheksidindiglukonat - sjampo - 20 mg/ ml / 20 mg/ ml

Norge - norsk - Statens legemiddelverk

infectopharm arzneimittel und consilium gmbh - metylfenidathydroklorid - tablett - 10 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

avimedical b.v. - itraconazole - antimycotics for systemisk bruk, triazole derivater, itrakonazol - avian - for behandling av aspergillosis og candidiasis i følgesvenn fugler,.